Company to Begin Generating Revenue in Second Quarter of 2013
Alimera Will Host a Conference Call at 4:30 PM ET Today
ATLANTA, GA, March 21, 2013 — Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter ended December 31, 2012.
“We are about to begin the commercial launch of ILUVIEN®. Product is in our European warehouse, and our distribution channels and commercial infrastructure are well positioned,” said Dan Myers, president and chief executive officer of Alimera Sciences. “The training of our sales force has been completed and our teams are currently on the ground in Germany and the UK driving demand for ILUVIEN. We will begin shipping as soon as we receive a required acceptance from the Medicine and Health products Regulatory Agency, on the intended commercial batch size. Based on the increasing positive feedback we continue to receive, we believe that ophthalmologists in Europe are eager to prescribe ILUVIEN for their chronic DME patients who are considered insufficiently responsive to available therapies.”
Market Access Update
On January 23, 2013, Alimera announced that it had received final published guidance from the UK’s National Institute of Health and Clinical Excellence (NICE), indicating that ILUVIEN is not a cost-effective treatment for chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. In response to this, Alimera submitted a simple patient access
The following information was filed by Alimera Sciences Inc (ALIM) on Thursday, March 21, 2013 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Alimera Sciences Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed, and by Alimera Sciences Inc.
Ticker: ALIM CIK: 1267602 Form Type:10-K Annual Report Accession Number: 0001267602-13-000008 Submitted to the SEC: Thu Mar 28 2013 4:17:15 PM EST Accepted by the SEC: Thu Mar 28 2013 Period: Monday, December 31, 2012 Industry: Pharmaceutical Preparations